JP7302903B2 - Ｈａｐｌｎ１を含む軟骨関連疾患、あるいはその症状の予防用、改善用または治療用の組成物 - Google Patents

Ｈａｐｌｎ１を含む軟骨関連疾患、あるいはその症状の予防用、改善用または治療用の組成物 Download PDF

Info

Publication number
JP7302903B2
JP7302903B2 JP2021549676A JP2021549676A JP7302903B2 JP 7302903 B2 JP7302903 B2 JP 7302903B2 JP 2021549676 A JP2021549676 A JP 2021549676A JP 2021549676 A JP2021549676 A JP 2021549676A JP 7302903 B2 JP7302903 B2 JP 7302903B2
Authority
JP
Japan
Prior art keywords
hapln1
cartilage
protein
osteoarthritis
growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021549676A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022522144A (ja
Inventor
テ・キョン・キム
ジ・ミン・ジャン
Original Assignee
ハプルサイエンス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハプルサイエンス・インコーポレイテッド filed Critical ハプルサイエンス・インコーポレイテッド
Publication of JP2022522144A publication Critical patent/JP2022522144A/ja
Application granted granted Critical
Publication of JP7302903B2 publication Critical patent/JP7302903B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A23K20/147—Polymeric derivatives, e.g. peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Polymers & Plastics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Animal Husbandry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Materials For Medical Uses (AREA)
  • Fodder In General (AREA)
JP2021549676A 2019-02-28 2019-02-28 Ｈａｐｌｎ１を含む軟骨関連疾患、あるいはその症状の予防用、改善用または治療用の組成物 Active JP7302903B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2019/002418 WO2020175721A1 (ko) 2019-02-28 2019-02-28 Hapln1을 포함하는 연골 관련 질환 또는 증상의 예방, 개선 또는 치료용 조성물

Publications (2)

Publication Number Publication Date
JP2022522144A JP2022522144A (ja) 2022-04-14
JP7302903B2 true JP7302903B2 (ja) 2023-07-04

Family

ID=72238712

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021549676A Active JP7302903B2 (ja) 2019-02-28 2019-02-28 Ｈａｐｌｎ１を含む軟骨関連疾患、あるいはその症状の予防用、改善用または治療用の組成物

Country Status (14)

Country Link
US (1) US20230158106A1 (ko)
EP (1) EP3888664A4 (ko)
JP (1) JP7302903B2 (ko)
CN (1) CN113490500A (ko)
AU (1) AU2019431082B2 (ko)
BR (1) BR112021013538A2 (ko)
CA (1) CA3122250C (ko)
CO (1) CO2021009034A2 (ko)
IL (1) IL283551A (ko)
MX (1) MX2021008327A (ko)
PE (1) PE20230436A1 (ko)
SG (1) SG11202105767YA (ko)
WO (1) WO2020175721A1 (ko)
ZA (1) ZA202103815B (ko)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013527834A (ja) 2010-03-29 2013-07-04 マサチューセッツ インスティテュート オブ テクノロジー 抗炎症因子
JP2016531147A (ja) 2013-09-09 2016-10-06 フィジーン、エルエルシーＦｉｇｅｎｅ， Ｌｌｃ コンドロサイトまたは軟骨型細胞の再生のための遺伝子治療
JP7078712B2 (ja) 2017-08-29 2022-05-31 ハプルサイエンス・インコーポレイテッド Ｈａｐｌｎ１を有効成分として含む軟骨再生用組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2716751A1 (en) * 2012-10-08 2014-04-09 BioTime, Inc. Differentiated progeny of clonal progenitor cell lines
US10322125B2 (en) * 2013-02-22 2019-06-18 Emory University TGF-beta enhancing compositions for cartilage repair and methods related thereto
HUE053684T2 (hu) * 2015-01-07 2021-07-28 Pfizer Oldható FGFR3 csalik csontnövekedési rendellenességek kezelésére
AU2017207445B2 (en) * 2016-01-14 2023-12-07 Spinalcyte, Llc Cellular blend for the regeneration of chondrocytes or cartilage type cells
NZ756946A (en) * 2017-03-06 2022-07-01 Haplnscience Inc Composition for skin aging measurement, prevention, or alleviation, using hapln1

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013527834A (ja) 2010-03-29 2013-07-04 マサチューセッツ インスティテュート オブ テクノロジー 抗炎症因子
JP2016531147A (ja) 2013-09-09 2016-10-06 フィジーン、エルエルシーＦｉｇｅｎｅ， Ｌｌｃ コンドロサイトまたは軟骨型細胞の再生のための遺伝子治療
JP7078712B2 (ja) 2017-08-29 2022-05-31 ハプルサイエンス・インコーポレイテッド Ｈａｐｌｎ１を有効成分として含む軟骨再生用組成物

Also Published As

Publication number Publication date
PE20230436A1 (es) 2023-03-08
SG11202105767YA (en) 2021-06-29
US20230158106A1 (en) 2023-05-25
JP2022522144A (ja) 2022-04-14
AU2019431082A1 (en) 2021-07-01
EP3888664A1 (en) 2021-10-06
CA3122250C (en) 2023-12-12
MX2021008327A (es) 2021-08-11
CN113490500A (zh) 2021-10-08
CA3122250A1 (en) 2020-09-03
AU2019431082B2 (en) 2022-12-15
ZA202103815B (en) 2022-09-28
IL283551A (en) 2021-07-29
WO2020175721A1 (ko) 2020-09-03
BR112021013538A2 (pt) 2021-09-14
CO2021009034A2 (es) 2021-07-30
EP3888664A4 (en) 2021-12-15

Similar Documents

Publication Publication Date Title
CN107223153B (zh) 包含源于正分化成软骨细胞之干细胞的外排体的用于软骨细胞分化诱导或软骨组织再生的组合物
KR20200104831A (ko) Hapln1을 포함하는 연골 관련 질환 또는 증상의 예방, 개선 또는 치료용 조성물
JP6786544B2 (ja) 成長ホルモン断片の使用
JP7078712B2 (ja) Ｈａｐｌｎ１を有効成分として含む軟骨再生用組成物
CN106232153B (zh) 用于移植和组织工程手术的fgf-18
US20020009432A1 (en) Therapeutic agent for cartilaginous diseases
JP7302903B2 (ja) Ｈａｐｌｎ１を含む軟骨関連疾患、あるいはその症状の予防用、改善用または治療用の組成物
JP7308151B2 (ja) ヒトｂｍｐ７タンパク質のバリアント
WO2020163766A1 (en) Periosteal skeletal stem cells in bone repair
KR20210087779A (ko) 조직 재생용 조성물
JP2021080184A (ja) 変形性関節症の予防又は治療剤、及び変形性関節症の予防又は治療用医薬組成物
RU2788162C2 (ru) Композиция для профилактики, облегчения или лечения заболеваний или симптомов, связанных с хрящами, включающая hapln1
US20230263835A1 (en) Composition for preventing or treating osteoarthritis, comprising mesenchymal stem cell expressing tumor necrosis factor-inducible gene 6
EP3712255A1 (en) Composition containing, as active ingredient, culture of chicken bone marrow-derived osteochondral progenitor cells for promoting osteogenesis or inducing chondrogenic differentiation
WO2019045451A1 (ko) Hapln1을 유효성분으로 함유하는 연골 재생용 조성물
WO2019246013A1 (en) Peptides to enhance bone growth, repair and cell function
Silveira Fibroblast growth factor and its role in the chondrogenesis of canine mesenchymal stromal cells in three-dimensional collagen scaffolds
CA2197869C (en) Therapeutic agent for cartilaginous diseases
JPH0859502A (ja) 軟骨障害治療剤
CN114786707A (zh) Gdf-5突变体用于治疗疼痛和软骨破坏的用途
Siebelt M. Siebelt MD 3 Waarsing PhD1, C. Müller PhD3, M. de Jong PhD2, H. Jahr PhD 4

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230320

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230426

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230522

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230615

R150 Certificate of patent or registration of utility model

Ref document number: 7302903

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150